Investment to accelerate innovations in biopharma development through Corporate Development Initiative

Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Simulations Plus Releases DILIsym® 11
Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
Modeling and simulation will be a key component for shift to non-animal methodologies
Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
Total revenue grew 23% year-over-year driven by strong growth in both software and services

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
Simulations Plus will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor.

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
Industry partners to provide funding and data to support ACAT™ model improvements

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
Total revenue up 31% year-over-year primarily driven by strong software growth

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
Funded collaboration will leverage current FDA partnership to include additional LAI technologies

Simulations Plus to Participate in the Stephens Annual Investment Conference
Simulations Plus to Participate in the Stephens Annual Investment Conference

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities

Simulations Plus Releases DILIsym® X
Updated quantitative systems toxicology (QST) software investigates and predicts drug-induced liver injury (DILI)

Simulations Plus Releases ADMET Predictor® Version 12
Enhancements in key models power HT-PBPK simulations and AI-driven drug design with unprecedented performance and accuracy.

Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum

Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals.

Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15
Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance